Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Sichuan Kelun Pharmaceutical (002422 CH)
Watchlist
106
Analysis
Health Care
•
China
Sichuan Kelun Pharmaceutical Co., Ltd. manufactures pharmaceutical products. The Company's products include large infusion products, tablets, capsules, antibiotic injection, lyophilized powder for injection, and traditional Chinese medicine.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Sichuan Kelun Pharmaceutical
•
22 Apr 2026 16:49
Primer: Sichuan Kelun Pharmaceutical (002422 CH) - Apr 2026
Sichuan Kelun Pharmaceutical is transitioning from a dominant player in China's infusion and generics market to an innovation-driven...
αSK Primers
136 Views
Share
bullish
•
Cross Asset Strategy
•
18 Nov 2025 14:49
•
Syndicated
CX Daily: How Chinese Expertise Opened Up $20 Billion African Mine
TOP STORIES How China Unlocked Simandou to Reshape the Global Iron Ore Trade On an October morning along the Atlantic coast of West Africa, a bulk...
Caixin Global
Follow
299 Views
Share
bullish
•
Thematic (Sector/Industry)
•
26 Oct 2025 08:30
APAC Healthcare Weekly (October 26) – Innovent, Akeso, Celltrion, Classys, Daiichi, Syngene, Cipla
Innovent Biologics announced collaboration with Takeda. FDA approves two additional indications for Celltrion's Humira biosimilar. Syngene is...
Tina Banerjee
Follow
896 Views
Share
bullish
•
Thematic (Sector/Industry)
•
17 Aug 2025 08:30
APAC Healthcare Weekly (Aug 17) – Fosun Pharma, Remegen, Astellas, Daewoong Pharma, Zydus, Lupin
Astellas, Remegen, and Daewoong Pharma announced positive trial results for their respective drug candidates. Fosun Pharma stuck outlicensing deal....
Tina Banerjee
Follow
966 Views
Share
bullish
•
GenScript Biotech
•
10 Sep 2026 20:51
Aequitas: Genscript Biotech Placement - Earnings-Led Inflection; Re-Rating May Limit Upside
Genscript Biotech is looking to raise up to US$300m from a primary placement. Proceeds are to be used for capacity expansion and platform...
Akshat Shah
Follow
107 Views
Share
1
2
3
4
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x